Hematology/Oncology

Top Story

Abbreviated high-dose interferon induction fails to prolong RFS in melanoma

Abbreviated high-dose interferon induction fails to prolong RFS in melanoma
February 23, 2017

Patients with surgically resected intermediate-level melanoma who received 4 weeks of high-dose IV interferon induction had identical RFS and OS rates as those who underwent observation, according to a phase 3 randomized study published in Journal of Clinical Oncology.

Further, patients who received high-dose interferon reported more treatment-related toxicities and lower quality of life.

FDA News

FDA approves Revlimid for myeloma maintenance after stem cell transplant

February 22, 2017
The FDA today expanded the approval of lenalidomide to include maintenance therapy for patients with multiple myeloma who underwent autologous hematopoietic stem cell…
In the Journals

Possible options for the future of health care

February 22, 2017
A perspective recently published in the New England Journal of Medicine provides some insight on what President Donald J. Trump can and cannot do, in light of his…
In the Journals

APRI, FIB4 guide esophageal varices screening in light of hemophilia, coinfection

February 22, 2017
The aspartate transaminase-platelet ratio index and Fibrosis-4 score were effective non-invasive markers to monitor fibrosis and correlated to the presence of esophageal…

Novel probe has potential to aid in margin detection during cancer surgery

February 22, 2017
Researchers in Australia have developed a novel optical fiber probe with high sensitivity for detecting and differentiating cancerous tissue from healthy tissue in…
More News Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video
Meeting News

VIDEO: SUSTAIN trial brings potential ‘disease-modifying’ treatment to sickle cell

February 6, 2017
More »
Featured
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement